Quarterly Pricing Pulse — Q3 2026

AbbVie filed four material events this quarter (April 29, May 12, June 22, July 6)—more than any other player. Each signals refinement to Botox and Juvéderm pricing and the Allē loyalty rebate program. For medspa owners, this is the canary in the coal mine: when the market leader adjusts rebates and loyalty mechanics, every injector's cost-of-goods and patient acquisition economics shift. Watch for:

• Rebate thresholds tightening — higher volume requirements to unlock the same rebate tier
• Tiered loyalty acceleration — faster point accumulation for higher-spend patients, slower for casual users
• Allē integration deepening — expect more friction if you're not plugged into their ecosystem

The frequency of filings suggests AbbVie is testing and iterating fast. If you haven't audited your Allē rebate structure against your actual patient mix this quarter, do it now.

Evolus filed three material events (May 4, June 12, July 8) focused on Jeuveau (Newtox) and the Evolus Rewards program. The pattern is unmistakable: Evolus is pricing aggressively to medspas and using rebates to steal share from Botox. This is where price wars start—not in patient-facing discounts, but in practitioner acquisition costs and rebate depth.

• Expect lower per-unit acquisition costs on Jeuveau if you're willing to commit volume
• Rewards program mechanics are likely more aggressive than Allē's baseline
• Competitive pressure on Botox margins — your Botox rebate may not keep pace with Jeuveau's offer

If you've been loyal to Botox, this quarter is the moment to run a side-by-side rebate and margin analysis. Evolus is betting you haven't.

Hims & Hers filed five material events (May 21, June 2, June 15, July 1, and more), Eli Lilly filed three (April 30, May 7, May 20), and Viking Therapeutics filed two (April 29, May 26). The signal: GLP-1 supply, pricing, and compounding rules are in flux. Telehealth competitors are capturing cash-pay GLP-1 patients; next-gen dual-agonists (VK2735) are coming; and compounding-rule changes are reshaping what medspas can legally and profitably offer.

• Compounded GLP-1 margins are under pressure as supply normalizes and telehealth scales
• Next-gen competitors (VK2735) will fragment the GLP-1 cash-pay market further
• Regulatory clarity on compounding is still evolving—your compliance posture matters

If GLP-1 is a material revenue line for you, this quarter demands a hard look at your sourcing, pricing, and patient acquisition cost vs. lifetime value.

The Beauty Health Company (HydraFacial) filed three material events (May 12, June 16, June 22); Apyx Medical (Renuvion) filed three (May 14, May 21, June 17); and Bausch Health (Solta) filed three (April 29, May 19, July 1). These filings suggest:

• HydraFacial consumable pricing is stabilizing or rising—expect higher per-treatment supply costs
• Renuvion adoption and safety data are being actively communicated—device pricing may hold or increase
• Solta (Thermage/Fraxel/Clear+Brilliant) is in flux—potential spin-off or M&A could disrupt support, pricing, and supply chains

For facial and body-contouring menus, monitor consumable costs closely. If Solta undergoes M&A, your service contracts and pricing may need renegotiation.

Multiple trials completed this quarter (Botox forehead, HArmonyCa, Restylane Lyft chin, filler comparatives), and several are recruiting (Merz's NT 201 platysma, Galderma's Restylane Lyft chin, filler innovators). The takeaway:

• New indications for existing products (platysma, chin augmentation) will expand treatment menus and create pricing opportunities
• Filler innovation is steady but incremental—no disruptive new category emerged this quarter
• Botulinum toxin remains the innovation focus for Merz and AbbVie

These trials rarely move pricing in real time, but they signal where manufacturers are investing and where patient demand may shift 12–18 months out.

1. Audit your rebate portfolio. Pull your actual rebate rates, volume thresholds, and point-accumulation mechanics for Botox, Juvéderm, Jeuveau, and any other key injectables. Compare them side-by-side. If Jeuveau's rebate is now higher than Botox's, your cost-of-goods just shifted—and your patient pricing may need to move too.

2. Stress-test your GLP-1 economics. If you offer compounded or branded GLP-1, model what happens if supply normalizes further, telehealth competitors cut prices, or new dual-agonists fragment your patient base. Know your break-even per patient and your patient lifetime value.

3. Lock in device and consumable contracts now. HydraFacial, Renuvion, and Solta are all in active corporate motion. Before year-end, renegotiate or renew your supply agreements to protect against mid-year price hikes or supply disruptions in 2027.

Q3 2026 was the quarter price wars moved from threat to reality. AbbVie, Evolus, and the GLP-1 market are all competing hard for your loyalty and your patient's wallet. Your margins are under pressure—but so are your competitors'. The practices that win Q4 and 2027 will be the ones that know their numbers, move fast on rebate arbitrage, and lock in supply contracts before the next round of corporate moves. Stay sharp.